Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 16:12:1756284819848631.
doi: 10.1177/1756284819848631. eCollection 2019.

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience

Ferdinando D'Amico  1 , Tommaso Lorenzo Parigi  1 , Gionata Fiorino  2 , Laurent Peyrin-Biroulet  3 , Silvio Danese  4
Affiliations
Review

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience

Ferdinando D'Amico et al. Therap Adv Gastroenterol. .

Abstract

Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.

Keywords: real-world experience; tofacitinib; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Gionata Fiorino served as a consultant and a member of Advisory Boards for MSD, Takeda Pharmaceuticals, AbbVie, Pfizer, Celltrion, Amgen, Sandoz, Samsung, and Janssen Pharmaceuticals. Laurent Peyrin-Biroulet received consulting fees from Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Pharmacosmos, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, and lecture fees from Merck, Abbvie, Takeda, Janssen, Ferring, Norgine, Tillots, Vifor, Mitsubishi, and HAC-pharma. Silvio Danese has served as a speaker, a consultant and an advisory board member for Abbvie, Ferring, Hospira, Johnson & Johnson, Merck, Millennium Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma, and Vifor. The other authors declare no conflicts of interest.

References

    1. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785–1794. - PubMed
    1. Loftus EV., Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504–1517. - PubMed
    1. Harbord M, Eliakim R, Bettenworth D, et al. European Crohn’s and Colitis Organisation (ECCO) third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 1512. - PubMed
    1. Cohen BL, Sachar DB. Update on antitumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ 2017; 357: j2505. - PubMed
    1. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet 2017; 389: 1756–1770. - PMC - PubMed

LinkOut - more resources